208 related articles for article (PubMed ID: 11049967)
21. Immune reconstitution in chronic lymphocytic leukemia.
Riches JC; Ramsay AG; Gribben JG
Curr Hematol Malig Rep; 2012 Mar; 7(1):13-20. PubMed ID: 22231031
[TBL] [Abstract][Full Text] [Related]
22. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia.
Cantwell M; Hua T; Pappas J; Kipps TJ
Nat Med; 1997 Sep; 3(9):984-9. PubMed ID: 9288724
[TBL] [Abstract][Full Text] [Related]
23. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells.
Buhmann R; Nolte A; Westhaus D; Emmerich B; Hallek M
Blood; 1999 Mar; 93(6):1992-2002. PubMed ID: 10068672
[TBL] [Abstract][Full Text] [Related]
24. Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression.
Melo-Cardenas J; Urquiza M; Kipps TJ; Castro JE
Cancer Gene Ther; 2012 May; 19(5):336-44. PubMed ID: 22402624
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia.
Anether G; Marschitz I; Tinhofer I; Greil R
Blood; 2002 Jan; 99(2):722-3. PubMed ID: 11799965
[No Abstract] [Full Text] [Related]
26. Gene transfer of CD154 and IL12 cDNA induces an anti-leukemic immunity in a murine model of acute leukemia.
Saudemont A; Buffenoir G; Denys A; Desreumaux P; Jouy N; Hetuin D; Bauters F; Fenaux P; Quesnel B
Leukemia; 2002 Sep; 16(9):1637-44. PubMed ID: 12200675
[TBL] [Abstract][Full Text] [Related]
27. Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes.
Mayr C; Bund D; Schlee M; Moosmann A; Kofler DM; Hallek M; Wendtner CM
Blood; 2005 Feb; 105(4):1566-73. PubMed ID: 15471955
[TBL] [Abstract][Full Text] [Related]
28. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells.
Furman RR; Asgary Z; Mascarenhas JO; Liou HC; Schattner EJ
J Immunol; 2000 Feb; 164(4):2200-6. PubMed ID: 10657675
[TBL] [Abstract][Full Text] [Related]
29. Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells.
Litzinger MT; Foon KA; Tsang KY; Schlom J; Palena C
Leuk Res; 2010 Oct; 34(10):1351-7. PubMed ID: 20122733
[TBL] [Abstract][Full Text] [Related]
30. B-cell chronic lymphocytic leukemia-derived dendritic cells stimulate allogeneic T-cell response and express chemokines involved in T-cell migration.
Łuczyński W; Stasiak-Barmuta A; Piszcz J; Iłendo E; Kowalczuk O; Krawczuk-Rybak M
Neoplasma; 2007; 54(6):527-35. PubMed ID: 17949237
[TBL] [Abstract][Full Text] [Related]
31. T cell activation following infection of primary follicle center lymphoma B cells with adenovirus encoding CD154.
Cantwell MJ; Wierda WG; Lossos IS; Levy R; Kipps TJ
Leukemia; 2001 Sep; 15(9):1451-7. PubMed ID: 11516107
[TBL] [Abstract][Full Text] [Related]
32. Adenovirus transduction to effect CD40 signalling improves the immune stimulatory activity of myeloma cells.
Bashey A; Cantwell MJ; Kipps TJ
Br J Haematol; 2002 Aug; 118(2):506-13. PubMed ID: 12139739
[TBL] [Abstract][Full Text] [Related]
33. CD40 ligand, Bcl-2 and apoptosis in B-chronic lymphocytic leukemia.
Hussein OA; Omran AA; Elnaggar AM; Fathy A
Egypt J Immunol; 2009; 16(2):27-36. PubMed ID: 22059351
[TBL] [Abstract][Full Text] [Related]
34. The potential of gene transfer into primary B-CLL cells using recombinant virus vectors.
Wendtner CM; Kofler DM; Mayr C; Bund D; Hallek M
Leuk Lymphoma; 2004 May; 45(5):897-904. PubMed ID: 15291346
[TBL] [Abstract][Full Text] [Related]
35. CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines.
Rieger R; Kipps TJ
Cancer Res; 2003 Jul; 63(14):4128-35. PubMed ID: 12874017
[TBL] [Abstract][Full Text] [Related]
36. Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia.
Biagi E; Rousseau R; Yvon E; Schwartz M; Dotti G; Foster A; Havlik-Cooper D; Grilley B; Gee A; Baker K; Carrum G; Rice L; Andreeff M; Popat U; Brenner M
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6916-23. PubMed ID: 16203783
[TBL] [Abstract][Full Text] [Related]
37. HSV amplicon-mediated delivery of LIGHT enhances the antigen-presenting capacity of chronic lymphocytic leukemia.
Tolba KA; Bowers WJ; Eling DJ; Casey AE; Kipps TJ; Federoff HJ; Rosenblatt JD
Mol Ther; 2002 Oct; 6(4):455-63. PubMed ID: 12377186
[TBL] [Abstract][Full Text] [Related]
38. In vitro engagement of CD3 and CD28 corrects T cell defects in chronic lymphocytic leukemia.
Bonyhadi M; Frohlich M; Rasmussen A; Ferrand C; Grosmaire L; Robinet E; Leis J; Maziarz RT; Tiberghien P; Berenson RJ
J Immunol; 2005 Feb; 174(4):2366-75. PubMed ID: 15699173
[TBL] [Abstract][Full Text] [Related]
39. Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors.
Wendtner CM; Kofler DM; Theiss HD; Kurzeder C; Buhmann R; Schweighofer C; Perabo L; Danhauser-Riedl S; Baumert J; Hiddemann W; Hallek M; Büning H
Blood; 2002 Sep; 100(5):1655-61. PubMed ID: 12176885
[TBL] [Abstract][Full Text] [Related]
40. IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells.
Pascutti MF; Jak M; Tromp JM; Derks IA; Remmerswaal EB; Thijssen R; van Attekum MH; van Bochove GG; Luijks DM; Pals ST; van Lier RA; Kater AP; van Oers MH; Eldering E
Blood; 2013 Oct; 122(17):3010-9. PubMed ID: 24014238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
